Aussie takes in stride slowing domestic inflation, bonds up

By Stella Qiu SYDNEY, Nov 30 (Reuters) - The Australian dollar held steady on Wednesday, taking in stride slowing inflation at home, while bonds jumped as investors priced in a likely lower peak in

BRIEF-Rio Tinto Plans Further Investment In Renewable Energy In The Pilbara

Nov 29 (Reuters) - Rio Tinto Ltd: * RIO TINTO PLANS FURTHER INVESTMENT IN RENEWABLE ENERGY IN THE PILBARA * PLANNING TO INVEST A FURTHER $600 MILLION IN RENEWABLE ENERGY ASSETS IN PILBARA * INVESTMENT

Stocks dip while U.S. crude gains on China hopes

By Sinéad Carew and Tom Wilson NEW YORK/LONDON (Reuters) - The S&P 500 closed lower on Tuesday as investors awaited guidance on the Federal Reserve's path of interest rate hikes, while U.S. oil

What to Watch in the Day Ahead - Wednesday, November 30

(The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at . Thomson One users

What to Watch in the Day Ahead - Wednesday, November 30

(The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at . Thomson One users

BRIEF-Immutep Enters Into Second Clinical Trial Collaboration Agreement With Merck KGaA, Darmstadt, Germany, And Pfizer For New Combination Study Of Its First-In-Class Lag-3 Candidate, Eftilagimod Alpha, And Avelumab To Treat Urothelial Cancer

Nov 29 (Reuters) - Immutep Ltd: * IMMUTEP ENTERS INTO SECOND CLINICAL TRIAL COLLABORATION AGREEMENT WITH MERCK KGAA, DARMSTADT, GERMANY, AND PFIZER FOR NEW COMBINATION STUDY OF ITS FIRST-IN-CLASS LAG-

Mount Burgess (ASX:MTB) updates on vanadium pentoxide, germanium and gallium contribution to Nxuu

Highlights,Mount Burgess (ASX:MTB) has released an update on the contribution of vanadium pentoxide, germanium and gallium to the Nxuu deposit.,The newly added mineralised domains occur above and within the Zn/Pb/Ag mineralised domains.,The inclusion has ...

Five key facts to know about First Au Limited (ASX:FAU)

Highlights,First Au Limited has its prime focus on building a strong project portfolio with major discoveries in its gold and base metal assets in Victoria, Western Australia, and South Australia,The results of historic work and geological settings have b...

Cyprium Metals’ (ASX:CYM) Australian portfolio in focus amid growing copper demand

Highlights,Copper plays a prominent role in connecting and delivering to the world a clean and efficient energy.,Globally, refined copper use is forecast to grow 3.7% to 26 million tonnes in 2023 and to 27 million tonnes in 2024, as per a government repor...


BRIEF-Immutep Enters Into Second Clinical Trial Collaboration Agreement With Merck KGaA, Darmstadt, Germany, And Pfizer For New Combination Study Of Its First-In-Class Lag-3 Candidate, Eftilagimod Alpha, And Avelumab To Treat Urothelial Cancer

Nov 29 (Reuters) - Immutep Ltd: * IMMUTEP ENTERS INTO SECOND CLINICAL TRIAL COLLABORATION AGREEMENT WITH MERCK KGAA, DARMSTADT, GERMANY, AND PFIZER FOR NEW COMBINATION STUDY OF ITS FIRST-IN-CLASS LAG-

BHP, OZL, SFR: How are these ASX copper stocks performing?

Here's a look at some of the important developments in three ASX copper stocks in 2022.

FEATURE-Australians fear for privacy as hackers steal personal data

* Cyber criminals target leading Australian companies * Government vows to find culprits, amends privacy rules * Need to limit the amount of data collected, experts say By Seb Starcevic MELBOURNE, Nov


What to Watch in the Day Ahead - Wednesday, November 30

(The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at . Thomson One users

What to Watch in the Day Ahead - Wednesday, November 30

(The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at . Thomson One users

BRIEF-Kogi Iron Says Entered Into A Binding Option Term Sheet To Acquire 100% Of Salar Verde

Nov 30 (Reuters) - Kogi Iron Ltd: * ENTERED INTO A BINDING OPTION TERM SHEET TO ACQUIRE 100% OF SALAR VERDE LITHIUM BRINE-CLAY PROJECT IN CHILE Source text for Eikon: Further company coverage:


NST to EVN: ASX gold stocks on radar as yellow metal’s prices shoot up

rest rates. Gold prices rose on Wednesday amid a weakening dollar and US Federal Reserve chief Jerome Powell’s aggressive stance on inflation. A weaker dollar enhances the appeal of bullion and makes it attractive for buyers who hold other...

Australia gains top spot in gold production; overtakes China for the first time

Australian gold miners have turned the corner around challenging times and helped the country in setting a new production record. Higher output by Australia’s major miners during the first half of 2020 helped the country surpass China as the ...

Gold rush on the cards amidst rising inflation and weak dollar

Summary Gold prices surged 8% during May, the highest monthly gain since July 2020. Fear of rise in inflation and weakening of dollar are catalysing the current price rise. Investors are keeping an eye on Treasury bond yields and inflation dat...


ASX 200 opens flat; Whitehaven, New Hope gain over 4%

Australian shares opened flat on Wednesday following a poor night on Wall Street.

ASX 200 likely to fall after poor night on Wall Street

The Australian share market is expected to open marginally lower Wednesday following a poor night on Wall Street.

ASX 200 opens flat; Fisher & Paykel up nearly 8%

Australian shares opened flat on Tuesday despite Wall Street ending lower in the overnight trade.


BRIEF-Immutep Enters Into Second Clinical Trial Collaboration Agreement With Merck KGaA, Darmstadt, Germany, And Pfizer For New Combination Study Of Its First-In-Class Lag-3 Candidate, Eftilagimod Alpha, And Avelumab To Treat Urothelial Cancer

Nov 29 (Reuters) - Immutep Ltd: * IMMUTEP ENTERS INTO SECOND CLINICAL TRIAL COLLABORATION AGREEMENT WITH MERCK KGAA, DARMSTADT, GERMANY, AND PFIZER FOR NEW COMBINATION STUDY OF ITS FIRST-IN-CLASS LAG-

BRIEF-Little Green Pharma Says Received Ethics Approval For Cbd Phase Iii Clinical Trial

Nov 30 (Reuters) - Little Green Pharma Ltd: * RECEIVED ETHICS APPROVAL FOR CBD PHASE III CLINICAL TRIAL Source text for Eikon: Further company coverage:

BRIEF-Mayne Pharma Says Return To Positive EBITDA Expected In FY24

Nov 30 (Reuters) - Mayne Pharma Group Ltd: * FOCUSED ON DRIVING IMPROVED PROFITABILITY AND CASH FLOW WITH RETURN TO POSITIVE EBITDA EXPECTED IN FY24 Source text for Eikon: Further company coverage:


COVID-19 Scare: Rising cases hit Australian healthcare system

Highlights,In Australia, COVID-19 patients admitted to hospitals hit a record high with over 5,433 people hospitalised,The healthcare system is under severe strain with the rising number of cases and healthcare workers going into isolation,In response to ...

Why is Australia relaxing border rules despite COVID-19 spike?

Highlights Despite a spike in COVID-19 tally, the Australian government has decided to relax restrictions over movement across borders. The border measures that restricted travellers from highly affected Southern Africa countries to Australia h...

Has COVID-19 pandemic proven more hostile to developing economies?

Highlights  Unlike advanced economies, developing countries would not be able to achieve pre-pandemic economic levels by 2023. As per the WHO, 85% of people in Africa have not received a single COVID-19 vaccine dose, while 36 countries hav...